Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer

Article ID	Journal	Published Year	Pages	File Type
8231315	International Journal of Radiation OncologyBiologyPhysics	2010	6 Pages	PDF

Abstract

Reirradiation (66 Gy in 2.2 Gy fractions) with concurrent and maintenance erlotinib (150 mg daily) for recurrent or new primary HNC is feasible.

Keywords

Erlotinib Reirradiation Head-and-neck cancer Recurrent

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

Initial Results of a Phase I Dose-Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and New Primary Head-and-Neck Cancer

Authors

Kyle E. M.D., Steven J. M.D., David M.D., Madeleine M.D., Ph.D., John I. M.D., Nicos M.D., Ranee M.D., Barbara M.D., John M.D., Robyn B.S., Miriam M.D., Roger M.D., Antonio M.D., Changhu M.D.,